

## Supplemental Table 1. Eligibility criteria to receive LuPSMA radionuclide treatment

### Inclusion criteria to receive LuPSMA

---

- Histopathological confirmed adenocarcinoma of the prostate
- Confirmed metastatic castration-resistant prostate cancer (testosterone levels below 50 ng/dL)
- Failure of standard treatments, including taxane-based chemotherapy (docetaxel, cabazitaxel) and androgen-signaling-targeted inhibitor (abiraterone, enzalutamide, or both), unless patients were unsuitable or refused these standard treatment regimens
- Progressive disease by prostate-specific antigen according to PCWG2 criteria or radiographic progression according to RECIST 1.1 criteria
- ECOG performance status score of 2 or lower
- Life expectancy greater than 3 months
- Hemoglobin concentration greater than 90 g/L
- Platelet count greater than  $110 \times 10^9/L$
- Neutrophil count greater than  $1.5 \times 10^9/L$
- PSMA-avid lesions on the screening PSMA-targeted PET

### Exclusion criteria:

---

- Presence of active infection or symptomatic viral hepatitis
  - Myocardial infarction or thromboemboly within the last 6 months
  - Heart insufficiency grade II-IV according to the New York Heart Association (NYHA).
  - Brain metastases
  - Active secondary malignoma
  - Acute or chronic glomerulonephritis
  - Untreated hydronephrosis
  - Nephrotoxic comedication
  - Previous radiation of the spine column or the pelvis including >25% of the bone marrow
-